Canaccord analyst Edward Nash lowered the firm’s price target on Travere Therapeutics to $15 from $35 and keeps a Buy rating on the shares. The firm said despite the disappointing outcome of the PROTECT study, since the chronic slope results were statistically significant and therefore meet the EMA’s requirement, management anticipates hearing back the review opinion from CHMP on the marketing application for sparsanten in IgAN around year-end.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TVTX:
- Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
- Wayfair upgraded, Deere downgraded: Wall Street’s top analyst calls
- Travere Therapeutics price target lowered to $14 from $30 at Evercore ISI
- Travere Therapeutics price target lowered to $18 from $32 at H.C. Wainwright
- Travere Therapeutics price target lowered to $18 from $25 at Guggenheim